Shire to buy Baxalta for US$32bn to create global leader in rare diseases

摘要

Shire has agreed a US$32bn takeover of Baxalta. Under the agreement, Dublin-based Shire will pay $47.50 a share for Baxalta. The transaction is expected to close in the middle of this year. Flemming Ornskov, Shire's Chief Executive, said a combination of the two companies would create the leading biotechnology company focused on treatments for rare diseases, with projected revenue of more than $20bn by 2020.